Importantly, the loss of the wildtype TP53 allele after the TP53R248Q mutagenesis of the first allele (p53 loss-of-heterozygosity = TP53Q/−) or homozygous TP53Q/Q is a prerequisite for mutp53R248Q gain-of-functions to drive tumor aggressiveness in CRC [59]. The gene discussed is TP53; the disease is neoplasm.